TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 15764730

Group type: COMPARATOR
Intervention: Arterial Hb‐CO concentrations in patients at stable conditions
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Arterial Hb‐CO concentrations in patients at exacerbations
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Arterial Hb‐CO concentrations in patients at stage III
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Arterial Hb‐CO concentrations in patients at stage IV
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Arterial Hb‐CO
Number of subjects: 58

Group type: COMPARATOR
Intervention: Arteriovenous Hb‐CO differences in patients at exacerbations
Number of subjects: 58
Study: 12352887

Group type: EXPERIMENTAL
Intervention: Oral itraconazole solution (200 mg every 12 hr)
Number of subjects: 188

Group type: COMPARATOR
Intervention: Intravenous/oral fluconazole (400 mg every 24 hr)
Number of subjects: 188

Group type: EXPERIMENTAL
Intervention: Oral itraconazole solution
Number of subjects: 188

Group type: COMPARATOR
Intervention: Intravenous/oral fluconazole
Number of subjects: 188
Study: 10224587

Group type: EXPERIMENTAL
Intervention: Mail intervention
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: Mail plus telephone intervention
Number of subjects: 136

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 136
Study: 8852867

Group type: EXPERIMENTAL
Intervention: 10-mg baclofen
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: 20-mg baclofen
Number of subjects: 7
Study: 1839722

Group type: EXPERIMENTAL
Intervention: Chlorhexidine treatment (ethyl cellulose containing chlorhexidine)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo polymer
Number of subjects: 30

Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 30
Study: 6662171

Group type: EXPERIMENTAL
Intervention: slow-release disopyramide phosphate (DR) 300 mg twice daily
Number of subjects: 12

Group type: COMPARATOR
Intervention: long-acting propranolol (PR) 1 X 160 mg daily
Number of subjects: 12
Study: 31689943

Group type: EXPERIMENTAL
Intervention: Isomaltulose beverage (GI 32)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Sucrose beverage (GI 65)
Number of subjects: 70
Study: 29427533

Group type: EXPERIMENTAL
Intervention: VeinViewer®
Number of subjects: 40

Group type: COMPARATOR
Intervention: Standard practice
Number of subjects: 40
Study: 27371449

Group type: EXPERIMENTAL
Intervention: Phototherapy before training sessions
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo after training sessions
Number of subjects: 48
Study: 24552555

Group type: EXPERIMENTAL
Intervention: Usual care + brief ACT-based intervention (five group therapy sessions integrating educational topics on heart-healthy behaviours with acceptance and mindfulness skills)
Number of subjects: 168

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 168
Study: 22136711

Group type: EXPERIMENTAL
Intervention: 8 g/d of fish oil (1.6 g/d EPA+DHA; n=17)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: 8 g/d of oxidised fish oil (1.6 g/d EPA+DHA; n=18)
Number of subjects: 54

Group type: COMPARATOR
Intervention: 8 g/d of high-oleic sunflower oil (n=19)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Both fish oil groups (8 g/d of fish oil and 8 g/d of oxidised fish oil)
Number of subjects: 54
Study: 19130965

Group type: EXPERIMENTAL
Intervention: Endoscope-assisted partial parotidectomy
Number of subjects: 38

Group type: COMPARATOR
Intervention: Conventional partial parotidectomy
Number of subjects: 38
Study: 18661414

Group type: EXPERIMENTAL
Intervention: Intravenous low molecular weight iron dextran (ID)
Number of subjects: 339

Group type: COMPARATOR
Intervention: Sodium ferrigluconate complex (SFGC)
Number of subjects: 339

Group type: COMPARATOR
Intervention: Iron sucrose (IS)
Number of subjects: 339

Group type: COMPARATOR
Intervention: Overall comparison of ID, SFGC, and IS
Number of subjects: 339

Group type: EXPERIMENTAL
Intervention: Drug discontinuation
Number of subjects: 339

Group type: EXPERIMENTAL
Intervention: Anaphylactoid reaction
Number of subjects: 339
Study: 16029455

Group type: EXPERIMENTAL
Intervention: Meropenem (MPM)
Number of subjects: 232

Group type: COMPARATOR
Intervention: Piperacillin/tazobactam (P/T)
Number of subjects: 232
Study: 11975426

Group type: EXPERIMENTAL
Intervention: Brotizolam 0.25 mg
Number of subjects: 40

Group type: COMPARATOR
Intervention: Zopiclone 7.5 mg
Number of subjects: 40
Study: 10030617

Group type: EXPERIMENTAL
Intervention: Contrast sensitivity measured with sine-wave grating patches at varying luminance and eccentricity levels.
Number of subjects: 18
Study: 7722762

Group type: EXPERIMENTAL
Intervention: Dual energy x-ray absorptiometry (DXA)
Number of subjects: 69
Study: 2185299

Group type: EXPERIMENTAL
Intervention: 2 mg glypressin intravenously (i.v.)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 7379678

Group type: EXPERIMENTAL
Intervention: Bile salts (5 mM, pH 5.5, 280 mOsm, 37 degrees C)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Saline solution without bile salts
Number of subjects: 8
Study: 30006846

Group type: EXPERIMENTAL
Intervention: SILS + 1
Number of subjects: 198

Group type: COMPARATOR
Intervention: CLS
Number of subjects: 198

Group type: EXPERIMENTAL
Intervention: SILS + 1 and CLS
Number of subjects: 198
Study: 30594237

Group type: EXPERIMENTAL
Intervention: 20 min of cycle ergometry at 50‐60% of maximum heart rate
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 20 min of exercise at 70‐80% of maximum heart rate
Number of subjects: 0

Group type: COMPARATOR
Intervention: 20 min of quiet reading
Number of subjects: 0
Study: 27061165

Group type: EXPERIMENTAL
Intervention: History of substance use disorder (SUD)
Number of subjects: 143

Group type: COMPARATOR
Intervention: Control (No history of substance use disorder)
Number of subjects: 143
Study: 24675910

Group type: EXPERIMENTAL
Intervention: Eccentric training (ECCT)
Number of subjects: 105

Group type: COMPARATOR
Intervention: Concentric control (CONCC)
Number of subjects: 105

Group type: COMPARATOR
Intervention: Eccentric control (ECCC)
Number of subjects: 105
Study: 22089177

Group type: EXPERIMENTAL
Intervention: Jiawei Qing'e Fang (JQF)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 72
Study: 20636718

Group type: EXPERIMENTAL
Intervention: Combined treatment with uric acid (1 g) and rtPA
Number of subjects: 420

Group type: COMPARATOR
Intervention: Vehicle alone (control)
Number of subjects: 420
Study: 17644313

Group type: EXPERIMENTAL
Intervention: Aripiprazole
Number of subjects: 0

Group type: COMPARATOR
Intervention: Haloperidol
Number of subjects: 0
Study: 16645532

Group type: EXPERIMENTAL
Intervention: Cimicifuga racemosa (CR) 40 mg/day
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Conjugated estrogens (CE) 0.6 mg/day
Number of subjects: 62

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 62
Study: 12507049

Group type: EXPERIMENTAL
Intervention: Training with the dominant hand
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Training with the subdominant hand
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Training with both hands
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Bimanual training
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Unimanual training
Number of subjects: 25
Study: 10690159

Group type: EXPERIMENTAL
Intervention: Aspartame
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 1 MJ simple carbohydrate
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 1 MJ high-fat
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: All drinks combined
Number of subjects: 10
Study: 8579032

Group type: EXPERIMENTAL
Intervention: Enalapril
Number of subjects: 6797

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6797
Study: 1902411

Group type: EXPERIMENTAL
Intervention: Diet plus glibenclamide (DPG)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Diet (D)
Number of subjects: 14
Study: 6762167

Group type: EXPERIMENTAL
Intervention: Torasemide 60 mg
Number of subjects: 12

Group type: COMPARATOR
Intervention: Furosemide 120 mg
Number of subjects: 12
Study: 29370424

Group type: EXPERIMENTAL
Intervention: Dapagliflozin 5 mg
Number of subjects: 220

Group type: EXPERIMENTAL
Intervention: Dapagliflozin 10 mg
Number of subjects: 220

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 220

Group type: EXPERIMENTAL
Intervention: Dapagliflozin 5 mg and 10 mg
Number of subjects: 220
Study: 27261171

Group type: EXPERIMENTAL
Intervention: Manville Moves exercise intervention using virtual-reality exergaming bicycles (cybercycles) integrated into physical education classes.
Number of subjects: 0
Study: 25559494

Group type: EXPERIMENTAL
Intervention: Alcohol consumption
Number of subjects: 15

Group type: COMPARATOR
Intervention: Water consumption
Number of subjects: 15
Study: 23384091

Group type: EXPERIMENTAL
Intervention: Rupatadine oral solution (1 mg/ml)
Number of subjects: 360

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 360
Study: 20939473

Group type: EXPERIMENTAL
Intervention: Low molecular weight heparin (LMWH) 5000 U/day (high dose group)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Low molecular weight heparin (LMWH) 2500 U/day (low dose group)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control group (no LMWH)
Number of subjects: 90
Study: 18391338

Group type: EXPERIMENTAL
Intervention: Monitoring simulated maternal-fetal heart rate signals
Number of subjects: 72
Study: 16601362

Group type: EXPERIMENTAL
Intervention: Nicotine gum (4 mg)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 10
Study: 15115965

Group type: EXPERIMENTAL
Intervention: Peginterferon alfa-2a plus ribavirin (n = 14)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Interferon alfa-2b plus ribavirin (n = 12)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Peginterferon alfa-2a plus placebo (n = 6)
Number of subjects: 32
Study: 10754612

Group type: EXPERIMENTAL
Intervention: Sedative and PPIA group
Number of subjects: 103

Group type: COMPARATOR
Intervention: Sedative group
Number of subjects: 103
Study: 8768417

Group type: EXPERIMENTAL
Intervention: Tagging files to remind a doctor to offer a smear during a consultation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Letters informing of clinic availability and suggesting appointment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Letters with specific appointments to attend a screening clinic
Number of subjects: 0

Group type: COMPARATOR
Intervention: Opportunistic screening (Control group)
Number of subjects: 0
Study: 1582790

Group type: EXPERIMENTAL
Intervention: 16% O2 + 5% CO2
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Pure oxygen (100% O2)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Pure oxygen (100% O2) + 5% CO2
Number of subjects: 10

Group type: COMPARATOR
Intervention: Mild hypoxia (16% O2)
Number of subjects: 10
Study: 3908125

Group type: EXPERIMENTAL
Intervention: Piretanide 6 mg once daily
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Piretanide 6 mg twice daily
Number of subjects: 0

Group type: COMPARATOR
Intervention: Hydrochlorothiazide 50 mg/amiloride 5 mg twice daily (HCT/A)
Number of subjects: 0
Study: 31543957

Group type: EXPERIMENTAL
Intervention: Educational intervention to trainee principal investigators
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Positive reinforcement intervention via an email nudge
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Feedback regarding the educational programme
Number of subjects: 20
Study: 28834178

Group type: EXPERIMENTAL
Intervention: Essential oils mouth rinse
Number of subjects: 60

Group type: COMPARATOR
Intervention: Dental flossing
Number of subjects: 60
Study: 26404425

Group type: EXPERIMENTAL
Intervention: Spray cryotherapy
Number of subjects: 50

Group type: COMPARATOR
Intervention: Intralesional cryotherapy
Number of subjects: 50
Study: 26685904

Group type: EXPERIMENTAL
Intervention: Beating the Blues
Number of subjects: 691

Group type: EXPERIMENTAL
Intervention: MoodGYM
Number of subjects: 691

Group type: COMPARATOR
Intervention: Usual GP care
Number of subjects: 691
Study: 22658123

Group type: EXPERIMENTAL
Intervention: Finasteride 0.5% solution applied twice daily
Number of subjects: 77

Group type: COMPARATOR
Intervention: Placebo solution applied twice daily
Number of subjects: 77
Study: 20367104

Group type: EXPERIMENTAL
Intervention: Acellular dermal matrix allograft (ADMA) seeded with autologous gingival fibroblasts
Number of subjects: 10

Group type: COMPARATOR
Intervention: Subepithelial connective tissue graft (SCTG)
Number of subjects: 10
Study: 18948799

Group type: EXPERIMENTAL
Intervention: Laparoscopic-assisted surgery
Number of subjects: 601

Group type: COMPARATOR
Intervention: Open surgery
Number of subjects: 601

Group type: EXPERIMENTAL
Intervention: Laparoscopic-assisted surgery (converted to open)
Number of subjects: 601
Study: 15957830

Group type: EXPERIMENTAL
Intervention: Danshen injection (DSI) 60 ml once a day for 10 days
Number of subjects: 221

Group type: COMPARATOR
Intervention: Conventional treatment alone
Number of subjects: 221

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 221
Study: 11803077

Group type: EXPERIMENTAL
Intervention: Combined hepatitis A and B vaccine (Twinrix) administered on days 0, 7, and 21
Number of subjects: 0

Group type: COMPARATOR
Intervention: Simultaneous administration of monovalent hepatitis A and B vaccines
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combined hepatitis A and B vaccine (Twinrix)
Number of subjects: 0
Study: 10429000

Group type: EXPERIMENTAL
Intervention: Inhaled nitric oxide (I‐NO) therapy at doses of 1, 4, and 16 ppm.
Number of subjects: 155

Group type: COMPARATOR
Intervention: Inhaled nitric oxide (I‐NO) therapy (pooled doses) for treatment failures.
Number of subjects: 155

Group type: COMPARATOR
Intervention: Placebo group for treatment failures.
Number of subjects: 155
Study: 7552524

Group type: EXPERIMENTAL
Intervention: Resolution of critical limb ischaemia
Number of subjects: 82
Study: 2082861

Group type: EXPERIMENTAL
Intervention: Neutral feedback
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Feedback indicating painful electric shock
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Feedback indicating subnormal sexual arousal
Number of subjects: 54
Study: 347466

Group type: EXPERIMENTAL
Intervention: Diazepam
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Nordiazepam
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Amylobarbitone
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 31836942

Group type: EXPERIMENTAL
Intervention: Blastocyst-stage transfer
Number of subjects: 208

Group type: COMPARATOR
Intervention: Cleavage-stage transfer
Number of subjects: 208
Study: 31484531

Group type: EXPERIMENTAL
Intervention: Infertile women
Number of subjects: 720

Group type: COMPARATOR
Intervention: Fertile women
Number of subjects: 720
Study: 28107847

Group type: EXPERIMENTAL
Intervention: Funny videos
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Unfunny videos
Number of subjects: 90

Group type: COMPARATOR
Intervention: No videos (Control)
Number of subjects: 90
Study: 25381629

Group type: EXPERIMENTAL
Intervention: Tadalafil (20 mg/day)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 23430007

Group type: EXPERIMENTAL
Intervention: Educational video (6-min video about head and neck radiotherapy side effects)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Verbal information (control group)
Number of subjects: 38
Study: 17689633

Group type: EXPERIMENTAL
Intervention: Severe hypertensive disorders of pregnancy
Number of subjects: 216
Study: 15736915

Group type: EXPERIMENTAL
Intervention: Fish oil supplementation (1.3 g EPA and 0.9 g DHA per day) from week 30 of gestation (FO(pregn/lact))
Number of subjects: 44

Group type: COMPARATOR
Intervention: Fish oil supplementation (1.3 g EPA and 0.9 g DHA per day) from week 30 of gestation (FO(pregn))
Number of subjects: 44

Group type: COMPARATOR
Intervention: Control regimen (olive oil or no oil)
Number of subjects: 44
Study: 10883412

Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide (HCTZ, 12.5 mg daily)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Quinapril/HCTZ combinations
Number of subjects: 49
Study: 9111254

Group type: EXPERIMENTAL
Intervention: Laser photocoagulation of drusen
Number of subjects: 27

Group type: COMPARATOR
Intervention: Control (untreated eye)
Number of subjects: 27
Study: 8472720

Group type: EXPERIMENTAL
Intervention: verapamil 120 mg t.i.d.
Number of subjects: 1775

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 1775
Study: 2436462

Group type: EXPERIMENTAL
Intervention: Thrombin method (5,000 units/5 cc. X 2)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Ligature method
Number of subjects: 50
Study: 31419607

Group type: EXPERIMENTAL
Intervention: Health Check‐Up for Expectant Moms (HCEM), a computer‐delivered brief intervention with two booster sessions
Number of subjects: 250

Group type: COMPARATOR
Intervention: Computer‐delivered control condition
Number of subjects: 250
Study: 29062344

Group type: EXPERIMENTAL
Intervention: Formal hospital-based adult triage protocol
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Emergency department allocation
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Barriers to triage improvement
Number of subjects: 33
Study: 26928521

Group type: EXPERIMENTAL
Intervention: MenACWY‐TT (1 dose)
Number of subjects: 349

Group type: EXPERIMENTAL
Intervention: MenACWY‐TT (2 doses)
Number of subjects: 349

Group type: EXPERIMENTAL
Intervention: Booster dose of MenACWY‐TT
Number of subjects: 349

Group type: COMPARATOR
Intervention: Primary MenACWY‐TT dose (age-matched, meningococcal naive children)
Number of subjects: 349

Group type: EXPERIMENTAL
Intervention: MenACWY‐TT
Number of subjects: 349
Study: 24720919

Group type: EXPERIMENTAL
Intervention: Colchicine (0.5 mg twice daily)
Number of subjects: 267

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 267
Study: 22524495

Group type: EXPERIMENTAL
Intervention: Judgements of retention (JORs)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Judgements of learning (JOLs)
Number of subjects: 0
Study: 19934280

Group type: EXPERIMENTAL
Intervention: bupropion SR combined with brief counseling (group A)
Number of subjects: 205

Group type: EXPERIMENTAL
Intervention: bupropion SR combined with nonspecific psychological support in groups (NSGS) (group B)
Number of subjects: 205

Group type: EXPERIMENTAL
Intervention: bupropion SR combined with cognitive behavioral group therapy (CBGT) (group C)
Number of subjects: 205

Group type: COMPARATOR
Intervention: CBGT as the only approach (group D)
Number of subjects: 205

Group type: EXPERIMENTAL
Intervention: bupropion SR combined with NSGS (group B)
Number of subjects: 205

Group type: EXPERIMENTAL
Intervention: bupropion SR combined with CBGT (group C)
Number of subjects: 205
Study: 17258323

Group type: EXPERIMENTAL
Intervention: HAMD-17
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: Short scales
Number of subjects: 113
Study: 15340805

Group type: EXPERIMENTAL
Intervention: Ropivacaine 7.5%
Number of subjects: 100

Group type: COMPARATOR
Intervention: 0.9% saline (Control)
Number of subjects: 100
Study: 11641310

Group type: EXPERIMENTAL
Intervention: Perindopril (2 mg) and Indapamide (0.625 mg)
Number of subjects: 471

Group type: COMPARATOR
Intervention: Atenolol (50 mg)
Number of subjects: 471
Study: 9588696

Group type: EXPERIMENTAL
Intervention: Estradiol (100 microg by patch)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Progesterone (100 mg i.m.)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 8108665

Group type: EXPERIMENTAL
Intervention: Prednisolone 50 mg per day for 14 days, then 25 mg per day for another 14 days.
Number of subjects: 93

Group type: COMPARATOR
Intervention: Placebo tablets for the same time period (14 days of 50 mg, then 14 days of 25 mg).
Number of subjects: 93
Study: 2697953

Group type: EXPERIMENTAL
Intervention: Laser therapy using helium-neon, infrared, argon, and helium-cadmium lasers
Number of subjects: 300
Study: 163938

Group type: EXPERIMENTAL
Intervention: ABOB 1% solution applied topically
Number of subjects: 151

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 151
Study: 31113932

Group type: EXPERIMENTAL
Intervention: Gemtuzumab ozogamicin (GO)
Number of subjects: 942

Group type: COMPARATOR
Intervention: No Gemtuzumab ozogamicin (No-GO)
Number of subjects: 942
Study: 28085204

Group type: EXPERIMENTAL
Intervention: Progressive Resistance Training (PRT)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Aerobic Training (AT)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Control Group (AT)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Control Group (PRT)
Number of subjects: 15
Study: 25433580

Group type: EXPERIMENTAL
Intervention: Calcium Fructoborate 112 mg/day (CFB-1)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Calcium Fructoborate 56 mg/day (CFB-2)
Number of subjects: 0
Study: 23515980

Group type: COMPARATOR
Intervention: Standard triple therapy (pantoprazole 40 mg, clarithromycin 500 mg, and amoxicillin 1 g each administered twice daily for 10 days)
Number of subjects: 272

Group type: EXPERIMENTAL
Intervention: Sequential therapy (pantoprazole 40 mg plus amoxicillin 1 g twice daily for 5 days followed by pantoprazole 40 mg, clarithromycin 500 mg, and tinidazole 500 mg each administered twice daily for 5 days)
Number of subjects: 272

Group type: COMPARATOR
Intervention: Standard triple therapy
Number of subjects: 272

Group type: EXPERIMENTAL
Intervention: Sequential therapy
Number of subjects: 272

Group type: EXPERIMENTAL
Intervention: Both therapies
Number of subjects: 272
Study: 21749020

Group type: EXPERIMENTAL
Intervention: Extended-care program (face-to-face or telephone)
Number of subjects: 224

Group type: COMPARATOR
Intervention: Control condition (educational)
Number of subjects: 224
Study: 19916645

Group type: EXPERIMENTAL
Intervention: Implementation intention formation
Number of subjects: 261

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 261
Study: 16961694

Group type: EXPERIMENTAL
Intervention: 400 mg day(-1) micronized progesterone
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: 0.2 mg day(-1) oestradiol
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Combination of progesterone and oestradiol
Number of subjects: 49

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Withdrawal of hormone supplement
Number of subjects: 49
Study: 15179374

Group type: EXPERIMENTAL
Intervention: Enteral glutamine feeding for 48 hours (20% of amino acids replaced with glutamine)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Conventional feeding (isonitrogenous, isocaloric standard enteral feedings for 48 hours)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Enteral glutamine feeding for 48 hours
Number of subjects: 9